focus -WSS

focus

author：focus 2025-08-11 11:44:20 - browse：51

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Washington mulls new rules to avert another Change Healthcare

WSS

How CO2 helps viruses stay alive longer in the air

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Medicare Advantage's lean provider networks lead CMS complaints

Covid vaccine financial winners and losers, from Pfizer to Novavax

Merck drug for rare lung condition set for approval in U.S.

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Hollywood unions extend contract negotiations for actors

Illumina board agrees to spin off Grail, as divestment plans proceed

Cancer drug shortages should be causing more outrage

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Heart attack and stroke risk calculators need revising

There's no autism epidemic. It's an autism diagnosis epidemic

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How CO2 helps viruses stay alive longer in the air

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Wikipedia

FDA approves Moderna’s RSV vaccine, its second licensed product

Vertex Pharmaceuticals may move headquarters in Boston

The most pressing bird flu mysteries scientists want answered

Primary care physicians play key roles in Alzheimer's management

Covid vaccine financial winners and losers, from Pfizer to Novavax

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

knowledge

Wikipedia

explore

leisure time